Hypoplastic thrombocytopenia and platelet transfusion: therapeutic goals

References

• Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood. 1985;66(5):1105–1109.
   PubMed Web of Science ®Google Scholar
• Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev. 2004;18(3):153–167.
   PubMed Web of Science ®Google Scholar
• Blajchman MA, Senyi AF, Hirsh J, et al. Hemostatic function, survival, and membrane glycoprotein changes in young versus old rabbit platelets. J Clin Invest. 1981;68(5):1289–1294.
   PubMed Web of Science ®Google Scholar
• Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015;162(3):205–213.
   PubMed Web of Science ®Google Scholar
• Popovsky MA. Transfusion-related acute lung injury: three decades of progress but miles to go before we sleep. Transfusion. 2015;55(5):930–934.
   PubMed Web of Science ®Google Scholar
• Vassallo RR. Review: igA anaphylactic transfusion reactions. Part I. Laboratory diagnosis, incidence, and supply of IgA-deficient products. Immunohematology. 2004;20(4):226–233.
   PubMedGoogle Scholar
• Lee D, Contreras M, Robson SC, et al. Recommendations for the use of anti-D immunoglobulin for Rh prophylaxis. British blood transfusion society and the royal college of obstetricians and gynaecologists. Transfus Med. 1999;9(1):93–97.
   PubMed Web of Science ®Google Scholar
• Schiffer CA, Bohlke K, Delaney M, et al. Platelet transfusion for patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2018;36(3):283–299.
   PubMed Web of Science ®Google Scholar
• Kuehn B. Fatal sepsis linked to platelets. JAMA. 2018;320(6):540.
   Web of Science ®Google Scholar
• Etulain J, Negrotto S, Carestia A, et al. Acidosis downregulates platelet haemostatic functions and promotes neutrophil proinflammatory responses mediated by platelets. Thromb Haemost. 2012;107(1):99–110.
   PubMed Web of Science ®Google Scholar
• Schmidt AE, Refaai MA, Blumberg N. Platelet transfusion and thrombosis: more questions than answers. Semin Thromb Hemost. 2016;42(2):118–124.
   PubMed Web of Science ®Google Scholar
• Whitaker BI. The United States department of health and human services 2011 National blood collection and utilization survey. Bethesda, MD: National Institutes of Health, Department of Health and Human Services; 2011.
   Google Scholar
• Cameron B, Rock G, Olberg B, et al. Evaluation of platelet transfusion triggers in a tertiary-care hospital. Transfusion. 2007;47(2):206–211.
   PubMed Web of Science ®Google Scholar
• Estcourt LJ, Stanworth SJ, Murphy MF. Prophylactic platelet transfusions. Curr Opin Hematol. 2010;17(5):411–417.
   PubMed Web of Science ®Google Scholar
• Slichter SJ. Controversies in platelet transfusion therapy. Annu Rev Med. 1980;31:509–540.
   PubMed Web of Science ®Google Scholar
• Hamajima N, Sasaki R, Aoki K, et al. A notable change in mortality of aplastic anemia observed during the 1970s in Japan. Blood. 1988;72(3):995–999.
   PubMed Web of Science ®Google Scholar
• Baer MR, Bloomfield CD. Controversies in transfusion medicine. Prophylactic platelet transfusion therapy: pro. Transfusion. 1992;32(4):377–380.
   PubMed Web of Science ®Google Scholar
• Estcourt LJ, Birchall J, Lowe D, et al. Platelet transfusions in haematology patients: are we using them appropriately? Vox Sang. 2012;103(4):284–293.
   PubMed Web of Science ®Google Scholar
• Estcourt LJ, Birchall J, Allard S, et al. Guidelines for the use of platelet transfusions. Br J Haematol. 2017;176(3):365–394.
   PubMed Web of Science ®Google Scholar
• Blajchman MA, Slichter SJ, Heddle NM, et al. New strategies for the optimal use of platelet transfusions. Hematology Am Soc Hematol Educ Program. 2008;198–204.
   PubMedGoogle Scholar
• Estcourt LJ, Heddle N, Kaufman R, et al. Biomedical excellence for safer transfusion collaborative. The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. Transfusion. 2013;53(7):1531–1543.
   PubMed Web of Science ®Google Scholar
• Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis platelet transfusion strategy for hematologic cancers. New Engl J Med. 2013;368(19):1771–1780.
   PubMed Web of Science ®Google Scholar
• Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet. 2012;380(9850):1309–1316.
   PubMed Web of Science ®Google Scholar
• Stanworth SJ, Hudson CL, Estcourt LJ, et al. TOPPS study investigators. Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica. 2015;100(6):740–747.
   PubMed Web of Science ®Google Scholar
• Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. New Engl J Med. 2010;362(7):600–613.
   PubMed Web of Science ®Google Scholar
• Estcourt LJ, Stanworth SJ, Murphy MF. Platelet transfusions for patients with haematological malignancies: who needs them? Br J Haematol. 2011;154(4):425–440.
   PubMed Web of Science ®Google Scholar
• Mi JQ, Li JM, Shen ZX, et al. How to manage acute promyelocytic leukemia. Leukemia. 2012;26(8):1743–1751.
   PubMed Web of Science ®Google Scholar
• Estcourt LJ, Stanworth S, Doree C, et al. Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppresive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev. 2015;10:CD010984.
   Google Scholar
• Nevo S, Fuller AK, Zahurak ML, et al. Profound thrombocytopenia and survival of hematopoietic stem cell transplant patients without clinically significant bleeding, using prophylactic platelet transfusion triggers of 10 × 10 (9)or 20 × 10 (9)per L. Transfusion. 2007;47(9):1700–1709.
   PubMed Web of Science ®Google Scholar
• Yates SG, Sarode R. Is platelet transfusion necessary in cirrhotic patients with splenomegaly? Liver Int. 2014;34(1):164–165.
   PubMed Web of Science ®Google Scholar
• Heddle NM, Cook RJ, Tinmouth A, et al. SToP study investigators of the BEST collaborative. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood. 2009;113(7):1564–1573.
   PubMed Web of Science ®Google Scholar
• Fillmore WJ, Leavitt BD, Arce K. Dental extraction in the thrombocytopenic patient is safe and complications are easily managed. J Oral Maxillofac Surg. 2013;71(10):1647–1652.
   PubMed Web of Science ®Google Scholar
• Multizentrische Therapieoptimierungsstudie der akuten lymphatischen Leukämie bei Erwachsenen und Adoleszenten ab 15 Jahren (GMALL 07/2003) –therapieoptimierung durch Evaluation der minimalen Resterkrankung. THERAPIEPROTOKOLL. Stand: 3. Gefördert durch die Deutsche Krebshilfe; April 2003.
   Google Scholar
• Liumbruno G, Bennardello F, Lattanzio A, et al. Italian society of transfusion medicine and immunohaematology (SIMTI) work group. recommendations for the transfusion of plasma and platelets. Blood Transfus. 2009;7(2):132–150.
   PubMed Web of Science ®Google Scholar
• Heddle NM, Cook RJ, Sigouin C, et al. BEST collaborative (Biomedical excellence for safer transfusion). A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia. Transfusion. 2006;46(6):903–911.
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Hemostatic drugs. N Engl J Med. 1998;339(4):245–253.
   PubMed Web of Science ®Google Scholar
• Antun AG, Gleason S, Arellano M, et al. Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. Cancer. 2013;119(21):3784–3787.
   PubMed Web of Science ®Google Scholar
• Kalmadi S, Tiu R, Lowe C, et al. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Cancer. 2006;107(1):136–140.
   PubMed Web of Science ®Google Scholar
• Registry and results database of clinical studies, maintained by the National Library of Medicine (NLM) at the National Institutes of Health (NIH). [cited 2018 Oct]. Available from: https://clinicaltrials.gov/.
   Google Scholar
• Shpilberg O, Blumenthal R, Sofer O, et al. A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. Leuk Lymphoma. 1995;19(1–2):141–144.
   PubMed Web of Science ®Google Scholar
• Fricke W, Alling D, Kimball J, et al. Lack of efficacy of tranexamic acid in thrombocytopenic bleeding. Transfusion. 1991;31(4):345–348.
   PubMed Web of Science ®Google Scholar
• Lee DH, Blajchman MA. Platelet substitutes and novel methods of platelet preservation. In: Michelson AD, editor. Platelets. 2nd ed. San Diego, CA: Elsevier; 2007. p. 1297–1309.
   Google Scholar
• Poon MC. The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders. Transfus Med Rev. 2007;21(3):223–236.
   PubMed Web of Science ®Google Scholar
• Kuter DJ. New thrombopoietic growth factors. Blood. 2007;109(11):4607–4616.
   PubMed Web of Science ®Google Scholar
• Delaflor-Weiss E, Mintz PD. The evaluation and management of platelet refractoriness and alloimmunization.Transfus. Med Rev. 2000;14(2):180–196.
   Google Scholar
• Hillgruber C, Pöppelmann B, Weishaupt C, et al. Blocking neutrophil diapedesis prevents hemorrhage during thrombocytopenia. J Exp Med. 2015;212(8):1255–1266.
   PubMed Web of Science ®Google Scholar
• Desborough M, Hadjinicolaou AV, Chaimani A, et al. Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review. Cochrane Database Syst Rev. 2016;10:CD012055. Review.
   PubMedGoogle Scholar
• Webert KE, Arnold DM, Lui Y, et al. A new tool to assess bleeding severity in patients with chemotherapy-induced thrombocytopenia. Transfusion. 2012;52(11):2466–2474.
   PubMed Web of Science ®Google Scholar
• Ciaravino V, McCullough T, Cimino G, et al. Preclinical safety profile of plasma prepared using the INTERCEPT Blood System. Vox Sang. 2003;85(3):171–182.
   PubMed Web of Science ®Google Scholar
• Ciaravino V, McCullough T, Cimino G. The role of toxicology assessment in transfusion medicine. Transfusion. 2003;43(10):1481–1492.
   PubMed Web of Science ®Google Scholar
• van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood. 2003;101(6):2426–2433.
   PubMed Web of Science ®Google Scholar
• Infanti L, Stebler C, Job S, et al. Pathogen-inactivation of platelet components with the INTERCEPT Blood System: a cohort study. Transfus Apher Sci. 2011;45(2):175–181.
   PubMed Web of Science ®Google Scholar
• Lozano M, Knutson F, Tardivel R, et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol. 2011;153(3):393–401.
   PubMed Web of Science ®Google Scholar
• Sigle JP, Infanti L, Studt JD, et al. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components. Transfusion. 2013;53(8):1788–1797.
   PubMed Web of Science ®Google Scholar
• McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood. 2004;104(5):1534–1541.
   PubMed Web of Science ®Google Scholar
• Janetzko K, Cazenave JP, Kluter H, et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion. 2005;45(9):1443–1452.
   PubMed Web of Science ®Google Scholar
• Kerkhoffs JL, van Putten WL, Novotny VM, et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol. 2010;150(2):209–217.
   PubMed Web of Science ®Google Scholar
• Cid J, Escolar G, Lozano M. Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials. Vox Sang. 2012;103(4):322–330.
   PubMed Web of Science ®Google Scholar
• Vamvakas EC. Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system. Vox Sang. 2012;102(4):302–316.
   PubMed Web of Science ®Google Scholar
• Garban F, Guyard A, Labussière H, et al. for the evaluation of the efficacy of platelets treated with pathogen reduction process (EFFIPAP) study group. comparison of the hemostatic efficacy of pathogen-reduced platelets vs untreated platelets in patients with thrombocytopenia and malignant hematologic diseases. A randomized clinical trial. JAMA Oncol. 2018. DOI:10.1001/jamaoncol.2017.5123.
   PubMed Web of Science ®Google Scholar
• Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion. 2010;50(11):2362–2375.
   PubMed Web of Science ®Google Scholar
• Marschner S, Goodrich R. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother. 2011;38(1):8–18.
   PubMed Web of Science ®Google Scholar
• van der Meer PF, Ypma PF, van Geloven N, et al. Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial. Blood. 2018;132(2):223–231.
   PubMed Web of Science ®Google Scholar
• Estcourt LJ, Malouf R, Hopewell S, et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev. 2017;7:CD009072.
   PubMedGoogle Scholar
• Seltsam A, Müller TH. Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol. 2013;162(4):442–454.
   PubMed Web of Science ®Google Scholar
• Kickler TS. The challenge of platelet alloimmunization: management and prevention. Transfus Med Rev. 1990;4(4 Suppl 1):8–18.
   PubMedGoogle Scholar
• Benson K, Fields K, Hiemenz J, et al. The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding. Semin Oncol. 1993;20(5 Suppl 6):102–109.
   PubMed Web of Science ®Google Scholar
• Stanworth SJ, Navarrete C, Estcourt L, et al. Platelet refractoriness–practical approaches and ongoing dilemmas in patient management. Br J Haematol. 2015;171(3):297–305.
   PubMed Web of Science ®Google Scholar
• Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol. 2008;142(3):348–360.
   PubMed Web of Science ®Google Scholar
• Falkenburg JH, Marijt WA, Heemskerk MH, et al. Minor histocompatibility antigens as targets of graft-versus-leukemia reactions. Curr Opin Hematol. 2002;9(6):497–502.
   PubMed Web of Science ®Google Scholar
• Rebulla P. Refractoriness to platelet transfusion. Curr Opin Hematol. 2002;9(6):516–520.
   PubMed Web of Science ®Google Scholar
• Petz LD, Garratty G, Calhoun L, et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion. 2000;40(12):1446–1456.
   PubMed Web of Science ®Google Scholar
• Kickler TS, Ness PM, Braine HG. Platelet crossmatching: a direct approach to the selection of platelet transfusions for the alloimmunized thrombocytopenic patient. Am J Clin Pathol. 1988;90(1):69–72.
   PubMed Web of Science ®Google Scholar
• Heal JM, Cowles J, Masel D, et al. Antibodies to plasma proteins: an association with platelet transfusion refractoriness. Br J Haematol. 1992;80(1):83–90.
   PubMed Web of Science ®Google Scholar
• Arepally GM. Heparin-induced thrombocytopenia. Blood. 2017;129(21):2864–2872.
   PubMed Web of Science ®Google Scholar